Decreased menstrual flow
Conditions
Interventions
Experimental Group:Human-Derived Engineered Extracellular Matrix Lyophilized Powder Combined with Sodium Hyaluronate for Treatment
Control Group:Treatment with Lyophilized Powder (Without Human-Derived Engineered Extracellular Matrix) Combined with Sodium Hyaluronate
Sponsors
The Seventh Affiliated Hospital Sun Yat-sen University
Eligibility
Sex/Gender
Female
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Age: 20-45 years old, Female, Body Mass Index (BMI) 1.1 ng/ml; 6. The TCT test result is normal within one year, or both the TCT and HPV test results are normal within three years; 7. After providing full informed consent, the participant voluntarily participates in this study and is able to complete the follow-up as scheduled;
Exclusion criteria
Exclusion criteria: 1. Any individual with severe cardiovascular, pulmonary, hepatic, or renal diseases; those with chronic diseases such as diabetes mellitus, hypertension, hematological diseases, thromboembolic diseases, autoimmune diseases, etc.; or those with comorbid diseases that seriously endanger the participant's safety or affect their ability to complete this study; 2. Those with untreated sexually transmitted infections (STIs) such as AIDS, syphilis, gonorrhea, or chlamydia; those with unresolved vaginitis, pelvic inflammatory disease, or other genital tract infectious diseases; and those with untreated alcoholism, drug use, or drug addiction. 3. There is a malignant tumor or a suspected malignant tumor; 4. There are uterine organic lesions such as uterine malformation, adenomyosis, uterine fibroids, and endometrial hyperplasia, as well as reproductive organ lesions such as hydrosalpinx or ovarian cysts; 5. Those who have been pregnant before enrollment, or have had sexual intercourse after the onset of menstruation; 6. Those with mental illnesses, including severe hysteria, who lack the capacity for autonomy; 7. History of severe allergies, history of severe immunodeficiency; 8. People with poor adherence; 9. Have participated in other experimental studies in the recent 3 months; 10. Unable to understand the researcher's introduction or explanation of this study; 11. Other circumstances deemed unsuitable for participation in the study by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effective rate of endometrial thickness improvement during the periovulatory period; | — |
Secondary
| Measure | Time frame |
|---|---|
| Uterine Cavity Morphology;Menstrual blood volume;Subjects' Self-Assessment of Treatment Effect Satisfaction;Effective rate of endometrial thickness improvement during the periovulatory period (process); | — |
Countries
China
Contacts
Public ContactLi Tian
The Seventh Affiliated Hospital Sun Yat-sen University
Outcome results
None listed